Fresenius SE Income from Discontinued Operations 2016-2024 | FSNUY

Fresenius SE annual/quarterly income from discontinued operations history and growth rate from 2016 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
  • Fresenius SE income from discontinued operations for the quarter ending September 30, 2024 was $0.027B, a INF% increase year-over-year.
  • Fresenius SE income from discontinued operations for the twelve months ending September 30, 2024 was $0.027B, a INF% increase year-over-year.
  • Fresenius SE annual income from discontinued operations for 2023 was $0B, a NAN% decline from 2022.
  • Fresenius SE annual income from discontinued operations for 2022 was $0B, a NAN% decline from 2021.
  • Fresenius SE annual income from discontinued operations for 2021 was $0B, a NAN% decline from 2020.
Fresenius SE Annual Income from Discontinued Operations
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
Fresenius SE Quarterly Income from Discontinued Operations
(Millions of US $)
2024-09-30 $27
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $21.703B $24.011B
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $17.349B 17.58
DaVita (DVA) United States $14.249B 18.43
Encompass Health (EHC) United States $9.629B 22.70
Chemed (CHE) United States $8.394B 25.80
Elanco Animal Health (ELAN) United States $6.076B 14.46
Option Care Health (OPCH) United States $5.267B 24.96
RadNet (RDNT) United States $4.972B 110.11
LifeStance Health (LFST) United States $3.092B 0.00
Amedisys (AMED) United States $3.023B 21.51
Addus HomeCare (ADUS) United States $2.290B 26.87
Astrana Health (ASTH) United States $2.076B 28.39
U.S Physical Therapy (USPH) United States $1.337B 35.14
Pennant (PNTG) United States $0.945B 38.21
Aveanna Healthcare Holdings (AVAH) United States $0.945B 0.00
Atai Life Sciences (ATAI) Germany $0.252B 0.00
Bioqual (BIOQ) United States $0.055B 0.00
Daxor (DXR) United States $0.038B 0.00
Ontrak (OTRK) United States $0.007B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
IMAC Holdings (BACK) United States $0.002B 0.00
Psychemedics (PMD) United States $0.000B 0.00